DekaBank Deutsche Girozentrale Boosts Stock Holdings in Kenvue Inc. (NYSE:KVUE)

DekaBank Deutsche Girozentrale boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 8.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,146,742 shares of the company’s stock after acquiring an additional 90,140 shares during the period. DekaBank Deutsche Girozentrale owned 0.06% of Kenvue worth $20,742,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Manchester Capital Management LLC lifted its position in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. Mather Group LLC. bought a new position in Kenvue during the first quarter valued at $28,000. Riverview Trust Co bought a new position in Kenvue during the first quarter valued at $33,000. MV Capital Management Inc. lifted its position in Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after purchasing an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC bought a new position in Kenvue during the first quarter valued at $33,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

Kenvue stock opened at $23.39 on Monday. The stock has a market cap of $44.80 billion, a price-to-earnings ratio of 29.99, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.47. The firm has a 50-day moving average of $20.41 and a two-hundred day moving average of $19.82.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 EPS. On average, research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is currently 105.13%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of Kenvue in a research note on Wednesday, August 7th. Citigroup dropped their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Finally, UBS Group lifted their price target on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $21.44.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.